Wells Fargo & Company Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $6.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target reduced by investment analysts at Wells Fargo & Company from $8.00 to $6.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 244.83% from the stock’s previous close.

Several other equities research analysts have also issued reports on ZNTL. HC Wainwright lowered their target price on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. UBS Group dropped their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday. Finally, Guggenheim reduced their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Trading Up 4.8 %

Shares of NASDAQ:ZNTL opened at $1.74 on Thursday. Zentalis Pharmaceuticals has a 12-month low of $1.66 and a 12-month high of $18.07. The business has a 50 day moving average of $2.94 and a two-hundred day moving average of $3.27. The company has a market capitalization of $124.00 million, a PE ratio of -0.70 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. Equities research analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Erste Asset Management GmbH acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $37,000. Aigen Investment Management LP acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $41,000. Capstone Investment Advisors LLC purchased a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at $48,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after acquiring an additional 5,333 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.